TEVA-RIZATRIPTAN TABLET

Ország: Kanada

Nyelv: angol

Forrás: Health Canada

Aktív összetevők:

RIZATRIPTAN (RIZATRIPTAN BENZOATE)

Beszerezhető a:

TEVA CANADA LIMITED

ATC-kód:

N02CC04

INN (nemzetközi neve):

RIZATRIPTAN

Adagolás:

10MG

Gyógyszerészeti forma:

TABLET

Összetétel:

RIZATRIPTAN (RIZATRIPTAN BENZOATE) 10MG

Az alkalmazás módja:

ORAL

db csomag:

100

Recept típusa:

Prescription

Terápiás terület:

SELECTIVE SEROTONIN AGONISTS

Termék összefoglaló:

Active ingredient group (AIG) number: 0137841002; AHFS:

Engedélyezési státusz:

CANCELLED PRE MARKET

Engedély dátuma:

2015-10-16

Termékjellemzők

1
PRODUCT MONOGRAPH
Pr
TEVA-RIZATRIPTAN
rizatriptan benzoate tablets
5 mg and 10 mg rizatriptan (as rizatriptan benzoate)
5-HT
1
Receptor Agonist
MIGRAINE THERAPY
Teva Canada Limited
Date of Revision:
30 Novopharm Court
November 30, 2011
Toronto, Ontario
M1B 2K9
Control Number: 127063, 150938
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION...............................................................
3
SUMMARY PRODUCT INFORMATION
...............................................................................
3
INDICATIONS AND CLINICAL
USE.....................................................................................
3
CONTRAINDICATIONS
..........................................................................................................
3
WARNINGS AND
PRECAUTIONS.........................................................................................
4
ADVERSE
REACTIONS.........................................................................................................
10
DRUG INTERACTIONS
.........................................................................................................
15
DOSAGE AND
ADMINISTRATION.....................................................................................
17
OVERDOSAGE
.......................................................................................................................
18
ACTION AND CLINICAL PHARMACOLOGY
................................................................... 19
STORAGE AND
STABILITY.................................................................................................
21
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................... 21
PART II: SCIENTIFIC
INFORMATION....................................................................................
22
PHARMACEUTICAL
INFORMATION.................................................................................
22
CLINICAL
TRIALS............................................................................................